How to Enhance Recruitment of Individuals at Risk of Rheumatoid Arthritis into Trials Aimed at Prevention: Understanding the Barriers and Facilitators

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2021 Mar 9

PMID 33685929

Citations 17

Authors

Laurette van Boheemen

Marieke M Ter Wee

Bart Seppen

Dirkjan van Schaardenburg

Affiliations

Soon will be listed here.

Abstract

Objectives: Several trials to test the efficacy of a pharmacological intervention aimed at primary prevention of rheumatoid arthritis (RA) are ongoing or have recently been completed. A common issue in these trials is the severe difficulty with patient recruitment. In order to enhance recruitment, this qualitative study identified barriers and facilitators of individuals at risk of RA to participate in a prevention trial.

Methods: Individuals at risk of developing RA (ie, arthralgia with anticitrullinated protein antibodies and/or rheumatoid factor without arthritis), who had previously been asked to participate in a prevention trial, participated in focus group discussions (n=18) exploring their facilitators and barriers for trial participation. Thematic analysis identified factors that were important in at-risk individuals' decision about trial participation.

Results: The prospect of personal benefit, the acknowledgement of one's symptoms and the desire to contribute to society facilitated trial participation. In contrast, misconception about what it means to be at risk, or about the aim of the prevention trial, negative views on trial medication, and a low perceived urgency to act on the possibility of developing RA versus a high perceived burden of participating in a trial discouraged participation.

Conclusions: To enhance inclusion in trials aimed to prevent RA, the results suggest to use strategies such as optimising education about RA, personal risk, trial aim and trial medication, explicitly addressing misconceptions and concerns, using tools to improve information provision, limiting study burden in trial design and encouraging physicians to mention trial participation.

Citing Articles

Does the use of statins alter the risk of rheumatoid arthritis? A systematic review and meta-analysis.

Pan X, Yang X, Ma P, Qin L PLoS One. 2024; 19(7):e0307599.

PMID: 39042634 PMC: 11265694. DOI: 10.1371/journal.pone.0307599.

Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects.

Toyoda T, Mankia K Drugs. 2024; 84(8):895-907.

PMID: 38954266 DOI: 10.1007/s40265-024-02061-0.

'What is my risk really?': a qualitative exploration of preventive interventions among individuals at risk of rheumatoid arthritis.

Chapman L, Siddle H, Serban S, Mankia K, Rooney C, Mustufvi Z Rheumatol Adv Pract. 2024; 8(2):rkae023.

PMID: 38495430 PMC: 10939459. DOI: 10.1093/rap/rkae023.

Can the General Public Be a Proxy for an "At-Risk" Group in a Patient Preference Study? A Disease Prevention Example in Rheumatoid Arthritis.

DiSantostefano R, Simons G, Englbrecht M, Humphreys J, Bruce I, Bywall K Med Decis Making. 2024; 44(2):189-202.

PMID: 38240281 PMC: 10865770. DOI: 10.1177/0272989X231218265.

Rheumatoid Arthritis: The Continuum of Disease and Strategies for Prediction, Early Intervention, and Prevention.

ONeil L, Alpizar-Rodriguez D, Deane K J Rheumatol. 2024; 51(4):337-349.

PMID: 38224993 PMC: 10984790. DOI: 10.3899/jrheum.2023-0334.

References

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce I, Buckley C . Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 2019; 20(1):429. PMC: 6633323. DOI: 10.1186/s13063-019-3403-7. View

Munro S, Spooner L, Milbers K, Hudson M, Koehn C, Harrison M . Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. BMC Rheumatol. 2019; 2:18. PMC: 6390586. DOI: 10.1186/s41927-018-0026-7. View

Stack R, van Tuyl L, Sloots M, van de Stadt L, Hoogland W, Maat B . Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford). 2014; 53(9):1646-53. DOI: 10.1093/rheumatology/keu159. View

Bos W, Dijkmans B, Boers M, van de Stadt R, van Schaardenburg D . Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2009; 69(3):571-4. DOI: 10.1136/ard.2008.105767. View

van Boheemen L, Turk S, van Beers-Tas M, Bos W, Marsman D, Griep E . Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open. 2021; 7(1). PMC: 7942258. DOI: 10.1136/rmdopen-2021-001591. View

Costenbader K, Brome D, Blanch D, Gall V, Karlson E, Liang M . Factors determining participation in prevention trials among systemic lupus erythematosus patients: a qualitative study. Arthritis Rheum. 2007; 57(1):49-55. DOI: 10.1002/art.22480. View

Combe B, Landewe R, Daien C, Hua C, Aletaha D, Alvaro-Gracia J . 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2016; 76(6):948-959. DOI: 10.1136/annrheumdis-2016-210602. View

van der Linden M, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga T . Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010; 62(12):3537-46. DOI: 10.1002/art.27692. View

Taylor H, Sugarman J, Pisetsky D, Bathon J . Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials. Ann Rheum Dis. 2006; 66(4):542-4. PMC: 1856056. DOI: 10.1136/ard.2006.059600. View

10.

Novotny F, Haeny S, Hudelson P, Escher M, Finckh A . Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. Joint Bone Spine. 2013; 80(6):673-4. DOI: 10.1016/j.jbspin.2013.05.005. View

11.

Udrea G, Dumitrescu B, Purcarea M, Balan I, Rezus E, Deculescu D . Patients' perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis. J Med Life. 2010; 2(2):227-31. PMC: 3018984. View

12.

Bos W, Wolbink G, Boers M, Tijhuis G, de Vries N, van der Horst-Bruinsma I . Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2009; 69(3):490-4. DOI: 10.1136/ard.2008.105759. View

13.

Harrison M, Spooner L, Bansback N, Milbers K, Koehn C, Shojania K . Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. PLoS One. 2019; 14(4):e0216075. PMC: 6483264. DOI: 10.1371/journal.pone.0216075. View

14.

Mosor E, Stoffer-Marx M, Steiner G, Raza K, Stack R, Simons G . I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2019; 72(3):360-368. PMC: 7064954. DOI: 10.1002/acr.23841. View

15.

Goekoop-Ruiterman Y, de Vries-Bouwstra J, Allaart C, van Zeben D, Kerstens P, Hazes J . Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52(11):3381-90. DOI: 10.1002/art.21405. View

16.

van Boheemen L, Bolt J, Ter Wee M, de Jong H, van de Sande M, van Schaardenburg D . Patients' and rheumatologists' perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020; 22(1):217. PMC: 7493385. DOI: 10.1186/s13075-020-02314-9. View

17.

de Jong P, Hazes J, Barendregt P, Huisman M, van Zeben D, van der Lubbe P . Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2012; 72(1):72-8. DOI: 10.1136/annrheumdis-2011-201162. View

18.

Cope A . Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies. Clin Ther. 2019; 41(7):1299-1311. DOI: 10.1016/j.clinthera.2019.04.014. View

19.

Simons G, Stack R, Stoffer-Marx M, Englbrecht M, Mosor E, Buckley C . Perceptions of first-degree relatives of patients with rheumatoid arthritis about lifestyle modifications and pharmacological interventions to reduce the risk of rheumatoid arthritis development: a qualitative interview study. BMC Rheumatol. 2019; 2:31. PMC: 6390593. DOI: 10.1186/s41927-018-0038-3. View

20.

van de Stadt L, Witte B, Bos W, van Schaardenburg D . A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2012; 72(12):1920-6. DOI: 10.1136/annrheumdis-2012-202127. View